Spongious fillers based on collagen-hydroxyapatite-eugenol acetate with therapeutic potential in bone cancer

Creative Commons License

Vladu A. F., Marin S., Neacșu I. A., Truşcă R. D., Albu Kaya M. G., KAYA D. A., ...More

Farmacia, vol.68, no.2, pp.313-321, 2020 (SCI-Expanded, Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.31925/farmacia.2020.2.17
  • Journal Name: Farmacia
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, International Pharmaceutical Abstracts
  • Page Numbers: pp.313-321
  • Keywords: Bone cancer, Collagen, Eugenol acetate, Fillers, Hydroxyapatite
  • Open Archive Collection: AVESIS Open Access Collection
  • Hatay Mustafa Kemal University Affiliated: Yes

Abstract

The aim of this study was to develop and characterize composite materials based on collagen, hydroxyapatite and eugenol acetate as new filler biomaterial for the reconstruction of the tissue damage arising after the resection in case of bone cancer. Composite gels consisting of collagen and hydroxyapatite in different proportions (Coll:HAp-100:0; 70:30; 40:60-w/w) and 0.5% eugenol acetate were lyophilized and spongious fillers were obtained. The fillers were characterized by water absorption, enzymatic degradation and examined by optical and scanning electron microscopy, EDS, FT-IR spectroscopy while eugenol acetate release from the compositions was also studied. The results showed that the filler with optimal composition (Coll-HAp-40:60 w/w) completely degrade over about 48 hours, the release capacity being longer during the 144 hours. The complex results obtained from physical-chemical, morphological and eugenol acetate release profile evaluation for the designed composite materials based on collagen and hydroxyapatite testify these formulations as drug delivery systems with potential applications as fillers in orthopaedic field in bone cancer.